General · EdgepediaSeptember 17, 20267 min read

Proteasome

The proteasome is a large, barrel-shaped protease complex found in eukaryotes, archaea, and some bacteria that degrades intracellular proteins, most of which are first tagged with the small protein ubiquitin. In eukaryotic cells it is the central executioner of the ubiquitin-proteasome system (UPS), the ATP-dependent pathway that removes misfolded, damaged, or excess proteins and thereby regulates processes including cell cycle progression, apoptosis, stress responses, signal transduction, and DNA repair.¹^•² The proteasome is abundant, constituting nearly 1% of cellular protein, and recent estimates suggest that as many as one-third of newly synthesized polypeptide chains are selected for rapid degradation by protein quality control.³ The discovery of ubiquitin-mediated protein degradation earned Aaron Ciechanover, Avram Hershko, and Irwin Rose the 2004 Nobel Prize in Chemistry.⁴

Key fact	Detail
Active form	The 26S proteasome (~2.5 MDa) combines a 20S catalytic core particle (CP) with one or two 19S regulatory particles (RP)¹
Core architecture	20S CP: four stacked heptameric rings in an α₇β₇β₇α₇ configuration; only β1, β2, and β5 retain intact active sites, giving six proteolytic sites per CP¹
Catalytic chemistry	A threonine protease; the active-site Thr sits at the N-terminus of the β subunit within a conserved Thr-Lys-Asp catalytic triad¹
Substrate tagging	K48-linked polyubiquitin chains signal proteasomal degradation; K63-linked chains instead route damaged organelles to the autophagy-lysosome pathway²
Inflammation-adapted form	The immunoproteasome replaces β1, β2, and β5 with inducible β1i (LMP2), β2i (MECL-1), and β5i (LMP7), upregulated by IFN-γ and TNF-α⁵
Approved inhibitors	Bortezomib (2003), carfilzomib (2012), and ixazomib (2015, the first oral proteasome inhibitor) are used in multiple myeloma⁶

Structure

The proteasome's catalytic engine is the 20S core particle, a highly conserved, barrel-shaped complex of 28 subunits arranged as four stacked heptameric rings. The two outer α rings form a gated entry channel that regulates substrate access, while the two inner β rings enclose the proteolytic chamber. In eukaryotes, seven distinct α-subunit paralogs form each outer ring and seven distinct β-subunit paralogs form each inner ring; only three of the seven β subunits (β1, β2, and β5) retain an intact active site, so each core particle carries six proteolytic active sites. These three subunits mediate caspase-like, trypsin-like, and chymotrypsin-like cleavage, respectively.¹^•⁵

The proteasome is a threonine protease, a mechanism distinct from the serine and cysteine protease families: the catalytic threonine is the N-terminal residue of the β subunit, exposed after autocatalytic removal of an N-terminal propeptide during assembly. The Thr residue participates in a conserved Thr-Lys-Asp catalytic triad that functions in both propeptide processing and substrate proteolysis.¹

For full activity, the 20S core associates with activators at one or both ends. The 19S regulatory particle, a roughly 700 kDa complex containing a heterohexameric ring of AAA+ ATPases (the Rpt subunits) plus lid components, recognizes ubiquitinated substrates, deubiquitylates them, unfolds the polypeptide, and translocates it into the core chamber. A 19S-capped core is conventionally called the 26S proteasome; physicochemical analysis places the fully capped, symmetrically assembled particle at approximately 30S, which is likely the functional unit in the cell. Other activators include PA28 (11S) and PA200/Blm10, and hybrid proteasomes with different activators on either end have been observed.¹^•⁷

Assembly of the ~2.5 MDa complex is carefully orchestrated. Eukaryotic core-particle biogenesis is chaperone-assisted and α-ring dependent: the heterodimeric chaperones Pba1–Pba2 (PAC1–PAC2 in humans) and Pba3–Pba4 (PAC3–PAC4) promote α-ring formation, while Ump1 (POMP or proteassemblin in humans) guides β-subunit incorporation and half-mer dimerization. β7 is always the last subunit to incorporate; its insertion completes half-mer formation and triggers dimerization of two half-proteasomes, after which the β-subunit propeptides autoprocess and Ump1 is degraded to yield the mature, active core.¹

The ubiquitin-proteasome pathway

Most proteasome substrates are marked by ubiquitin, a 76-residue protein attached covalently through a cascade of ubiquitin-activating (E1), conjugating (E2), and ligating (E3) enzymes. Which polyubiquitin linkage a substrate carries decides what happens to it: K48 linkages, formed at lysine 48, act chiefly as degradation marks for the proteasome, while chains joined through K63 send damaged organelles, ribosomes, endoplasmic reticulum, or mitochondria, along the autophagy-lysosome route.² The 19S regulatory particle performs the recognition, deubiquitylation, unfolding, and translocation steps that feed the substrate into the core's proteolytic chamber.¹

This pathway governs critical cellular processes including cell cycle progression, apoptosis, stress responses, and signal transduction, and it also handles proteins of the endoplasmic reticulum that fail to fold properly and are retrotranslocated back to the cytosol for destruction.²^•³ The system's importance was recognized with the 2004 Nobel Prize in Chemistry, awarded jointly to Aaron Ciechanover and Avram Hershko of the Technion in Haifa and Irwin Rose of the University of California, Irvine, "for the discovery of ubiquitin-mediated protein degradation."⁴

The immunoproteasome

Based on catalytic subunit composition, proteasomes are classified into three major forms: the constitutive proteasome, the immunoproteasome, and the thymoproteasome.⁵ The immunoproteasome is an inflammation-adapted variant in which the standard catalytic subunits β1 (PSMB6), β2 (PSMB7), and β5 (PSMB5) are replaced by their inducible isoforms β1i (LMP2, encoded by PSMB9), β2i (MECL-1, PSMB10), and β5i (LMP7, PSMB8). Pro-inflammatory cytokines, particularly interferon-gamma (IFN-γ), the most potent inducer, and tumor necrosis factor-alpha (TNF-α), drive this replacement through STAT1 and IRF1 signaling.⁵^•²

The immunoproteasome is constitutively expressed in hematopoietic cells and widely distributed across immune tissues, and it can be induced in non-immune cells under inflammatory conditions. Its substitution of catalytic subunits enhances chymotrypsin-like and trypsin-like activities and shifts cleavage preferences toward hydrophobic or basic C-terminal residues, which are optimally suited for loading onto major histocompatibility complex (MHC) class I molecules; this improves antigen presentation to cytotoxic T cells. It also clears oxidatively damaged proteins efficiently, including under conditions of reduced ATP availability when ubiquitin-dependent degradation is compromised, in part through association with the PA28α/β (11S) regulator.²^•⁵

Assembly of the immunoproteasome is rapid, approximately four times faster than that of the constitutive proteasome, because β5i binds directly to the assembly chaperone POMP (also known as UMP1), allowing a swift proteolytic response to immune and inflammatory stimuli. In mice, following infection, standard proteasomes in affected organs are swiftly replaced by newly synthesized immunoproteasomes.²

The immunoproteasome's roles are context-dependent. Transient induction supports clearance of damaged proteins and balanced inflammatory signaling, whereas sustained or dysregulated activation can reinforce NF-κB- and STAT-dependent inflammatory programs and contribute to tissue injury. It has been implicated in cardiovascular, respiratory, neurodegenerative, autoimmune, retinal, and oncological pathologies, and in the central nervous system it is expressed in microglia, astrocytes, endothelial cells, and certain neuronal subtypes with region- and time-dependent dynamics.²^•⁵

Proteasome inhibitors in medicine

Because rapidly dividing and antibody-producing cells are unusually sensitive to proteotoxic stress, proteasome inhibition has become a cornerstone therapy in multiple myeloma. Three inhibitors have received US FDA approval and are used routinely: the first-in-class bortezomib (approved 2003), the second-generation carfilzomib (2012), and ixazomib (2015), the first orally bioavailable proteasome inhibitor.⁶^•⁸

The agents differ in chemistry and pharmacology. Bortezomib and ixazomib are reversible peptide boronates, while carfilzomib is a peptide epoxyketone that binds irreversibly to the β5 subunit and inhibits the chymotrypsin-like activity; ixazomib also preferentially targets β5. Both boronates bind reversibly, but ixazomib has a much faster off-rate than bortezomib (18 versus 110 minutes half-time of dissociation).⁶^•⁹ Carfilzomib is given intravenously, unlike the subcutaneous route used for bortezomib, and carries a lower risk of clinically relevant drug-drug interactions than bortezomib; a meta-analysis found renal adverse events in 21% of carfilzomib-treated patients, with 8.3% grade 3 to 5 toxicities and acute kidney injury the most common renal toxicity.¹⁰^•¹¹

Clinical evidence supports the class. In a randomized trial of 722 patients with relapsed or refractory myeloma, adding ixazomib to lenalidomide and dexamethasone extended median progression-free survival to 20.6 months versus 14.7 months with placebo (HR, 0.66; P = .016).¹¹ In a trial of 792 patients comparing carfilzomib, lenalidomide, and dexamethasone against lenalidomide plus dexamethasone, median overall survival reached 48.3 months versus 40.4 months after a median follow-up of 67.1 months (HR, 0.79; one-sided P = .009).¹¹

Selective targeting of the immunoproteasome is a newer direction. β5i-specific inhibitors such as ONX 0914 and the epoxyketone KZR-616 have shown therapeutic potential in preclinical models by curbing cytokine storms and proteotoxic stress while sparing constitutive proteasome activity, with applications explored in autoimmune and cardiovascular disease.²^•⁹

References

Topic: Encyclopedia › Life and health › Biological foundations › Biochemistry and metabolism › Protein families and complexes › Biomolecular complexes and assemblies › Proteasome and ubiquitin-system assemblies

Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026; Oct 21, 2026 · Edited: Sep 30, 2026; Oct 21, 2026 · Last review: Oct 21, 2026

Notice something wrong?